Industry leading TCR pipeline targeting solid tumors

Cancer is a leading cause of death worldwide and is characterized by the uncontrolled growth of abnormal cells whose ability to evade the immune system is key. Adaptimmune’s affinity enhanced T-cell therapies work with the immune system to improve detection and targeting of cancer cells, resulting in the destruction of those cancer cells. We believe that the unique potential of immunotherapy will revolutionize the treatment of oncology in the future and Adaptimmune is at the forefront of immunotherapy development. 

SPEAR® T-cell therapies targeting MAGE-A4, and AFP are progressing through clinical studies in multiple solid tumors. The clinical studies for SPEAR® T-cell therapies targeting MAGE-A10 have been closed.

Our Pipeline

Adaptimmune is developing an industry-leading T-cell therapy pipeline in solid tumors, and has a deep pipeline of identified and proprietary targets for further product development.

Completed stage *Bladder, Melanoma, Head & Neck, Ovarian, Non-small cell lung cancer (NSCLC), Esophageal, Gastric, Synovial sarcoma, MRCLS ** Site specific protocol amendment with MD Anderson Cancer Center MRCLS=myxoid/round cell liposarcoma; EGJ: esophagogastric junction cancers Allogeneic/ HiT Phase 1 trial Hepatocellular carcinoma ADP-A2AFP AFP SURPASS-2 Esophageal and EGJ Cancers Initiating in 2021 SURPASS Focus on lung, Esophageal, head & neck and bladder cancers ADP-A2M4CD8 SPEARHEAD-2 Head & neck Combo with pembro SPEARHEAD-1 Synovial sarcoma, MRCLS Radiation sub study* Multiple tumors** Phase 1 Trial Multiple tumors* ADP-A2M4 MAGE A4 Program Therapy PreClinical Phase 1 Phase 2/3 EU ODD and Prime RMAT & ODD


The ADP-A2M4 (MAGE-A4) SPEAR T-cell therapy is directed to a member of the MAGE family of cancer testis antigen expressed in many solid tumor cell types.

Learn More


Our first “next-generation therapy” is the ADP-A2M4CD8 SPEAR T-cell therapy. Unlike the ADP-A2M4CD8 SPEAR T-cells therapy, these cells also express the CD8α co-receptor alongside the engineered TCR that targets MAGE-A4.

Learn More


Our ADP-A2AFP product is being used to treat patients with hepatocellular carcinoma (liver cancer).

Learn More


The ADP-A2M10 (MAGE-A10) T-cell therapy is directed to a member of the MAGE family of cancer-testis antigens expressed in several solid tumor cell types.

Learn More